{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T17:40:16Z","timestamp":1787161216207,"version":"build-2736575974"},"reference-count":16,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.ygyno.2015.10.007","type":"journal-article","created":{"date-parts":[[2015,10,16]],"date-time":"2015-10-16T00:29:06Z","timestamp":1444955346000},"page":"429-432","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Comparison of 5-day MTX and 5-day ETP treatment results and early predictors of drug resistance to 5-day MTX in patients with post-molar low-risk gestational trophoblastic neoplasia"],"prefix":"10.1016","volume":"139","author":[{"given":"Shoko","family":"Kizaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunori","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6638-7389","authenticated-orcid":false,"given":"Hideo","family":"Matsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Usui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makio","family":"Shozu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2015.10.007_bb0005","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1200\/JCO.2002.07.166","article-title":"Low-risk persistent gestational trophoblastic disease: outcome after initial treatment with low-dose methotrexate and folic acid from 1992 to 2000","volume":"20","author":"McNeish","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2015.10.007_bb0010","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1016\/S0002-9378(96)70229-6","article-title":"Treatment of low-risk metastatic gestational trophoblastic tumors with single-agent chemotherapy","volume":"174","author":"Roberts","year":"1996","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2015.10.007_bb0015","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1159\/000009987","article-title":"SekiyaS.Comparison of chemotherapies with methotrexate, VP-16 and actinomycin-D in low-risk gestational trophoblastic disease. Remission rates and drug toxicities","volume":"46","author":"Matsui","year":"1998","journal-title":"Gynecol. Obstet. Investig."},{"key":"10.1016\/j.ygyno.2015.10.007_bb0020","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/0002-9378(95)90575-8","article-title":"Single-agent methotrexate chemotherapy for the treatment of nonmetastatic trophoblastic tumors","volume":"172","author":"Lurain","year":"1995","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2015.10.007_bb0025","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1200\/JCO.1996.14.10.2769","article-title":"Combination but not single-agent methotrexate chemotherapy for gestational trophoblastic tumors increase the incidence of second tumors","volume":"14","author":"Rustin","year":"1996","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2015.10.007_bb0030","unstructured":"Cancer Therapy Evaluation Program (CTEP). Common Terminology Criteria for Adverse Events (CTCAE) v4.0. http:\/\/ctep.cancer.gov\/protocolDevelopment\/electric_applications\/ctc.htm#ctc_40"},{"key":"10.1016\/j.ygyno.2015.10.007_bb0035","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1006\/gyno.2000.5813","article-title":"Combination chemotherapy with methotrexate, etoposide, and actinomycin D for high-risk gestational trophoblastic tumors","volume":"78","author":"Matsui","year":"2000","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2015.10.007_bb0040","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1200\/JCO.2010.30.4386","article-title":"Phase III trial of weekly methotrexate or pulsed dactinomycin for low-risk gestational trophoblastic neoplasia: a Gynecologic Oncology Group Study","volume":"29","author":"Osborne","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2015.10.007_bb0045","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1200\/JCO.2010.31.0151","article-title":"Treatment of low-risk gestational neoplasia","volume":"29","author":"Aghajanian","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2015.10.007_bb0050","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.ygyno.2004.11.011","article-title":"Relapse rate of patients with low-risk gestational trophoblastic tumor initially treated with single-agent chemotherapy","volume":"96","author":"Matsui","year":"2005","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2015.10.007_bb0055","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1006\/gyno.1994.1169","article-title":"5-day methotrexate for women with metastatic gestational trophoblastic disease","volume":"54","author":"Soper","year":"1994","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2015.10.007_bb0060","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0090-8258(86)90123-X","article-title":"Ten years' experience with methotrexate and folic acid as primary therapy for gestational trophoblastic disease","volume":"23","author":"Berkowitz","year":"1986","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2015.10.007_bb0065","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/0002-9378(82)90400-8","article-title":"Treatment of nonmetastatic gestational trophoblastic disease: results of methotrexate alone versus methotrexate-folic acid","volume":"144","author":"Smith","year":"1982","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2015.10.007_bb0070","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0002-9378(85)80178-2","article-title":"Methotrexate with citrovorum rescue in gestational trophoblastic disease","volume":"152","author":"Wong","year":"1985","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2015.10.007_bb0075","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1038\/sj.bjc.6605529","article-title":"The management and outcome of women with post-hydatidiform mole \u2018low-risk\u2019 gestational trophoblastic neoplasia, but hCG levels in excess of 100000IUl(\u22121)","volume":"102","author":"McGrath","year":"2010","journal-title":"Brit. J. Cancer."},{"key":"10.1016\/j.ygyno.2015.10.007_bb0080","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.ygyno.2012.03.039","article-title":"Treatment of nonmetastatic and metastatic low-risk gestational trophoblastic neoplasia: factors associated with resistance to single-agent methotrexate chemotherapy","volume":"125","author":"Chapman-Davis","year":"2012","journal-title":"Gynecol. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825815301566?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825815301566?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,18]],"date-time":"2018-09-18T15:28:14Z","timestamp":1537284494000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825815301566"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":16,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["S0090825815301566"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2015.10.007","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of 5-day MTX and 5-day ETP treatment results and early predictors of drug resistance to 5-day MTX in patients with post-molar low-risk gestational trophoblastic neoplasia","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2015.10.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}